Comparative study of trace metal concentration in the diagnosis of category III prostatitis Authors: Zhidi Lin, Muyan Li, Mingjin Zhang, Yimin Gong, Xiang Gan, Weiyuan Liang, Yanjun Tan, Chong Zhang, Qian Gao, Xiaoli Yang Published: 2024 ABSTRACT BackgroundChronic prostatitis (CP) is one of the general diseases in urological practice, with category III prostatitis being particularly prevalent. The trace metal abnormalities might be a primary cause of prostatitis, however, their specific roles in category III prostatitis remain largely unexplored.MethodIn total, 42 expressed prostatic secretion (EPS) samples from IIIa prostatitis patients, 42 from IIIb prostatitis patients, and 45 from controls were collected, along with 42 serum samples from IIIa prostatitis patients, 45 from IIIb prostatitis patients, and 50 from controls for analysis in this study. To investigate the diagnostic potential of trace metals in category III prostatitis, we analyzed the concentration of zinc (Zn), copper (Cu), calcium (Ca) and magnesium (Mg) in EPS and serum of patients with category III prostatitis and healthy controls using a flame atomic absorption spectrometer (FAAS).ResultsThe Results showed that the concentrations of Zn, Ca and Mg in both serum and EPS samples of all subjects with category III prostatitis were significantly different compared to controls (all P < 0.05), while Cu levels were significantly altered in all EPS samples (P < 0.000). In the category of IIIa prostatitis group, the levels of Zn, Ca, Mg in EPS, as well as Ca in serum were significantly reduced (all P < 0.000), whereas the serum Zn level was markedly elevated (P < 0.000). In the category IIIb prostatitis group, the EPS levels of Zn, Ca, Mg were decreased significantly (all P < 0.05), and the levels of serum Ca, Mg were markedly decreased (all P < 0.000), however, the EPS Cu level increased significantly (P < 0.05). Moreover, receiver operating characteristic (ROC) analysis showed that the levels of Mg and Zn/Mg in EPS had better diagnostic value for category IIIa prostatitis (Area Under the ROC Curve(AUC) = 0.796, 0.791, respectively, all P < 0.0001); while Cu and Cu/Ca levels exhibited better diagnostic value for category IIIb prostatitis (AUC = 0.880, 0.901, respectively, all P < 0.0001).ConclusionSummarily, there are significant abnormalities in the concentrations of Cu, Mg, Ca, and Zn in EPS and serum samples of patients with category III prostatitis. The levels of Mg, Cu, Zn/Mg, Cu/Ca in EPS may serve as potential diagnostic markers for category III prostatitis. Introduction Chronic prostatitis (CP) is a common disease in adult male patients [1]. The U.S. National Institutes of Health (NIH) classified prostatitis into four categories in 1995, with category III, known as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), being the most prevalent. It accounts for 90-95% of all prostatitis diagnoses, while only about 8% of patients are affected by other categories [2, 3]. The estimated prevalence of CP/CPPS in the male population is 15% [4–6]. According to the latest version of the NIH consensus classification, the diagnosis of CP/CPPS is based on whether presence of white blood cells (WBCs) in expressed prostatic secretion (EPS), the first voided urine (VB3) after prostate massage, or in semen analysis [7]. Within this classification, CP/CPPS is further divided into two forms: IIIa, which refers to inflammatory CP/CPPS with WBCs present in semen, EPS, or VB3, and IIIb, which refers to non-inflammatory CP/CPPS with no WBCs detected in these fluids [6]. CP/CPPS is characterized by discomfort in the pelvic, genital, and suprapubic areas and is often associated with urinary symptoms and sexual dysfunction [6, 8]. Studies suggest that CP/CPPS may be caused by various factors, including oxidative stress (OS), abnormal immune response, intra-prostatic urinary reflux, pathogen infection, neurological and endocrine system dysfunction, and Th17 cell-driven autoimmunity [7–10]. However, due to the lack of definitive causative factors, the etiology and pathogenesis of chronic prostatitis remain unclear, making diagnosis challenging for urologists, and treatment outcomes often unsatisfactory. Metals play a vital role in various aspects of human health, as multiple metal ions, such as copper (Cu), zinc (Zn), calcium (Ca), and iron (Fe), are present in the human body. These ions are crucial components of several metalloproteins and are essential for maintaining overall health by participating in various metabolic and biochemical processes [11, 12]. Imbalanced trace metals can lead to diseases [13]. Research indicates that balanced levels of trace minerals, including Fe, Zn, selenium (Se) and Cu, are essential to prevent the progression of chronic inflammation like periodontitis [14]. Moreover, research suggests that lower blood manganese levels are associated with a higher risk of glaucoma [15]. Additionally, an imbalance of trace metals can contribute to cancer development through complex mechanisms involving DNA repair, oxidative damage, disturbance of signal transduction pathways, and maintenance of redox homeostasis, potentially leading to metal-induced carcinogenicity [16]. In recent years, studies have increasingly focused on the specific role of metal ions in various diseases, including prostatitis. It is well known that the adult male prostate accumulates significant amounts of trace metals such as zinc (Zn), calcium (Ca), and selenium (Se). Research has reported that both Zn and cadmium (Cd) are associated with the development of prostate diseases [17, 18], and trace metal abnormalities might be a primary cause of prostatitis [19]. In a healthy prostate, Zn accumulation is higher than in any other glandular organ [20], its levels are reported to decrease significantly [21]. Based on this knowledge, we aimed to investigate the concentrations of Cu, Zn, Ca, and Mg, in both EPS and serum of patients with CP/CPPS, as well as in healthy controls. Our goal was to determine whether changes in trace metal concentrations in CP/CPPS are significant compared to healthy controls and to explore potential new strategies for the diagnosis and treatment of category III prostatitis. Materials and methods Patients The patients included in this study were individuals with category III prostatitis who underwent physical examinations in the Guilin area of Guangxi, China. The sample collection was approved by the Guilin Medical University Ethics and Anthropology Committee (Number: GLMC202001011). The study was conducted in accordance with the Committee’s guidelines, with informed consent obtained from all participating patients. Clinical trial number: not applicable. All patients were diagnosed with the type III prostatitis (CP/CPPS) according to the NIH criteria. Eligibility requirements included: (1) negative results of bacterial culture of post-massage EPS; (2) no history of treatment with antibiotics and α-receptor blocker; (3) no history of urinary tract infections, benign prostatic hyperplasia, and other pelvic organ diseases. Exclusion criteria (1) urinary tract infection; (2) history of urinary cancer, surgery, radiotherapy, systemic chemotherapy; (3) unilateral testicular pain, active urethral stricture or bladder stone with pelvic symptoms, or any other urinary disease associated with lower urinary tract symptoms, any neurological disease or disorder affecting the bladder; (4) did not sign informed consent. Based on the NIH prostatitis classification standard, the participants were classified into 3 groups: category IIIa prostatitis group; category IIIb prostatitis group and control group. We obtained the serum and EPS from the same subjects at first. Thus 42 cases of IIIa prostatitis, 45 cases of IIIb prostatitis, and 50 cases of control patients were included in the experiment, and their serum and EPS were collected respectively. However, due to the limited sample volume of EPS, 5 cases of control, 3 cases of IIIb prostatitis EPS samples were consumed for pre-experiments. Therefore, 129 EPS samples (42 cases of IIIa prostatitis, 42 cases of IIIb prostatitis, and 45 cases of control) and 137 serum samples (42 cases of IIIa prostatitis, 45 cases of IIIb prostatitis, and 50 cases of control) were collected and analyzed in this study. The disease characteristics of the patients were shown in Table 1. Table 1Baseline of clinical and demographic characteristics of all subjects for flame absorption spectroscopy (FAAS) analysisHealthy control (n = 45)Category IIIa prostatitis (n = 42)Category IIIb prostatitis (n = 42)Agea36.85(6.56)41.71(8.02)38.83(7.29)Height (cm)168.92(3.82)169.11(3.53)166.49(4.60)Weight (kg)67.57(4.76)68.34(4.23)67.06(4.82)NIH-CPSIb-19(4.25)20(3.00)WBC in EPS-+ (n = 11)--+ + (n = 8)--+ + + (n = 12)--+ + + + (n = 11)-SPL in EPS+ (n = 3)+ (n = 3)+ (n = 4)+ + (n = 2)+ + (n = 9)+ + (n = 6)+ + + (n = 13)+ + + (n = 20)+ + + (n = 22)+ + + + (n = 22)+ + + + (n = 9)+ + + + (n = 8)+ + + + + (n = 5)+ + + + + (n = 1)+ + + + + (n = 2)WBC, white blood cell; EPS, expressed prostatic secretion; SPL, small particle of lecithin, lecithin corpuscles. + of WBC in EPS: +,10–20 leukocytes/High Power field (HP); + +, 21–30 leukocytes/HP; + + +, 31–40 leukocytes/HP; + + + +, 41–50 leukocytes/HP. + of SPL in EPS: +, none or scattered; + +, 1/4 of the visual field; + + +, 1/2 of the visual field; + + + +, 3/4 of the visual field, + + + + +, full of visiona, mean (standard deviation)b, medians (interquartile range) Table 1Baseline of clinical and demographic characteristics of all subjects for flame absorption spectroscopy (FAAS) analysisHealthy control (n = 45)Category IIIa prostatitis (n = 42)Category IIIb prostatitis (n = 42)Agea36.85(6.56)41.71(8.02)38.83(7.29)Height (cm)168.92(3.82)169.11(3.53)166.49(4.60)Weight (kg)67.57(4.76)68.34(4.23)67.06(4.82)NIH-CPSIb-19(4.25)20(3.00)WBC in EPS-+ (n = 11)--+ + (n = 8)--+ + + (n = 12)--+ + + + (n = 11)-SPL in EPS+ (n = 3)+ (n = 3)+ (n = 4)+ + (n = 2)+ + (n = 9)+ + (n = 6)+ + + (n = 13)+ + + (n = 20)+ + + (n = 22)+ + + + (n = 22)+ + + + (n = 9)+ + + + (n = 8)+ + + + + (n = 5)+ + + + + (n = 1)+ + + + + (n = 2)WBC, white blood cell; EPS, expressed prostatic secretion; SPL, small particle of lecithin, lecithin corpuscles. + of WBC in EPS: +,10–20 leukocytes/High Power field (HP); + +, 21–30 leukocytes/HP; + + +, 31–40 leukocytes/HP; + + + +, 41–50 leukocytes/HP. + of SPL in EPS: +, none or scattered; + +, 1/4 of the visual field; + + +, 1/2 of the visual field; + + + +, 3/4 of the visual field, + + + + +, full of visiona, mean (standard deviation)b, medians (interquartile range) Baseline of clinical and demographic characteristics of all subjects for flame absorption spectroscopy (FAAS) analysis WBC, white blood cell; EPS, expressed prostatic secretion; SPL, small particle of lecithin, lecithin corpuscles. + of WBC in EPS: +,10–20 leukocytes/High Power field (HP); + +, 21–30 leukocytes/HP; + + +, 31–40 leukocytes/HP; + + + +, 41–50 leukocytes/HP. + of SPL in EPS: +, none or scattered; + +, 1/4 of the visual field; + + +, 1/2 of the visual field; + + + +, 3/4 of the visual field, + + + + +, full of vision a, mean (standard deviation) b, medians (interquartile range) Blood sample collection Blood sample collection was performed in the morning before eating. Serum was collected by allowing the blood to coagulate for 30 min, centrifuged at 1200×g for 10 min at 4 °C. And then, serum samples were stored at -80 °C until assays. All blood samples were collected prior to the administration of any diagnosis. EPS sample collection EPS fluids were collected in 1.5 mL tubes directly from the genitals after the patients’ prostates were massaged by urologist. Part of the EPS was taken for routine microscopic examination and bacterial culture and the rest of EPS was centrifugated in low speed to remove cell pellets/sediments. The supernatant aliquots were placed in a clean 1.5 mL centrifuge tube and stored at -80 °C before analysis. Trace metal concentration detection Cu, Zn, Ca and Mg concentration in both serum and EPS samples were determined using BH-5100 5-channel flame atomic absorption spectrometer (Bohui, Beijing, China) equipped with hollow cathode lamps (213.9 nm, 324.3 nm, 422.7 nm, 285.2 nm, respectively). The levels of Cu, Zn, Ca and Mg were calculated using standard curve method (all r > 0.995), which performed using several certified reference materials from General Administration of Quality, Inspection and Quarantine of the People’s Republic of China (GBW(E) 080915–080917). The unit of Cu, Zn was µmol/L, while the unit of Ca and Mg was mmol/L. All serum and EPS samples were processed using special detection reagent kit for human elements by atomic absorption spectrometer (Bohui, Beijing, China): a total of 40 µL serum or EPS sample was obtained by adding 1.2 mL of Bohui multi-elemental detection reagents and shaken for inspection (the dilution was 31). Linearity of four elements were generated, the dilutions of samples were 20%, 40%, 60%, 80% and 100% respectively (all r>0.99). QC measurements to the baseline stability trace elements did not exceed 0.005 Abs. Recovery rates were all > 96%, and the sample carrying rate of four elements were low (all values<5%). Sensitivity was characterized by the levels of Cu, Zn, Ca and Mg which were less than 0.035, 0.015, 0.080, 0.040 mg/L/1%, respectively. The upper limit of precision was set at 0.1% (Abs > 0.1). Materials used in the experiment including reagents, quality product and element standard liquid were all manufactured by Beijing Bohui Innovation Technology Co., Ltd. And the method could refer to our pervious article [22]. Statistical analysis The SPSS software 19.0 and Medcalc software were used to perform statistical analysis. Mann-Whitney U test and Kruskal-Wallis test used to compare the concentration of Cu, Zn, Ca, Mg and the element ratio among patients with category IIIa and category IIIb prostatitis and the healthy control group. Pearson correlation was used to analyze the correlation between the levels of Cu, Zn, Ca, Mg and the element ratio in all participants’ serum and EPS, the test level was α = 0.05. And the P value < 0.05 was considered statistically significant. The receiver operating characteristic (ROC) curve is used to determine the diagnostic value and the optimal cut-off value for each trace metal are defined as the point on the ROC curve with the largest Youden index (sensitivity + specificity-1). Results Parameters of descriptive statistics for the concentration of metals in serum and EPS In this study, we analyzed the concentration of Cu, Zn, Ca and Mg in serum and EPS of CP/CPPS patients and control by flame atomic absorption spectrophotometry, respectively. Table 2 showed specific information of them. Firstly, compared to the control group, the contents of Zn, Ca and Mg in both serum and EPS samples of all subjects with CP/CPPS had significant changes, while the level of Cu changed significantly only in all EPS samples. And in the single category IIIa prostatitis group, the level of Ca and Mg decreased significantly in EPS compared with healthy controls (all P < 0.01), same as serum Ca (P < 0.01); serum Zn level increased (P < 0.01), on the contrary, EPS Zn level decreased obviously (P < 0.01); and the level Cu in EPS and serum had no palpable changes (P > 0.05). Then in the independent category IIIb prostatitis group, just like the category IIIa prostatitis group, EPS Zn, Ca and Mg decreased markedly (P < 0.05), also the levels of serum Ca and Mg were lessened visibly (all P < 0.01). Differently, the EPS Cu level has an overt promotion (P < 0.01) while Zn level of serum has no difference in category IIIb prostatitis. Table 2Parameters of descriptive statistics for the content of metals in EPS and serumCu (µmol/l)Zn (µmol/l)Ca (mmol/l)Mg (mmol/l) EPS Healthy control(n = 45)mean3.21907.478.776.36median2.44928.248.456.75IQR3.1873.124.021.13Chi-Squarea12.2813.4114.7319.8pa 0.000 0.000 0.000 0.000 IIIa Group(n = 42)mean3.51794.976.154.75median3.42887.956.275.29IQR3.66162.794.182.74Zb-0.541-4.239-4.154-4.744pb0.589 0.000 0.000 0.000 IIIb Group(n = 42)mean8.57838.447.225.39median9.27910.716.465.89IQR4.51141.755.872.96Zb-5.629-2.056-2.446-2.905pb ` 0.000 0.040 0.014 0.004 Serum Healthy control(n = 45)mean16.34015.922.340.89median15.73015.292.350.88IQR6.1004.80.150.068Chi-Squarea0.0944.77221.75810.706pa0.759 0.029 0.000 0.001 IIIa Group(n = 42)mean17.31019.412.280.87median17.08018.842.270.86IQR3.7205.570.130.1Zb-1.690-3.944-3.673-1.506pb0.091 0.000 0.000 0.132IIIb Group(n = 45)mean15.45015.22.220.83median15.13015.882.240.83IQR4.3904.150.1250.095Zb-1.093-0.108-4.283-4.023pb0.2730.914 0.000 0.000 a, Kruskal-Wallis test; b, Mann-Whitney U test, compared to control group; IQR: Interquartile range (IQR) calculated as the upper quartile (XU) – lower quartile (XL) Table 2Parameters of descriptive statistics for the content of metals in EPS and serumCu (µmol/l)Zn (µmol/l)Ca (mmol/l)Mg (mmol/l) EPS Healthy control(n = 45)mean3.21907.478.776.36median2.44928.248.456.75IQR3.1873.124.021.13Chi-Squarea12.2813.4114.7319.8pa 0.000 0.000 0.000 0.000 IIIa Group(n = 42)mean3.51794.976.154.75median3.42887.956.275.29IQR3.66162.794.182.74Zb-0.541-4.239-4.154-4.744pb0.589 0.000 0.000 0.000 IIIb Group(n = 42)mean8.57838.447.225.39median9.27910.716.465.89IQR4.51141.755.872.96Zb-5.629-2.056-2.446-2.905pb ` 0.000 0.040 0.014 0.004 Serum Healthy control(n = 45)mean16.34015.922.340.89median15.73015.292.350.88IQR6.1004.80.150.068Chi-Squarea0.0944.77221.75810.706pa0.759 0.029 0.000 0.001 IIIa Group(n = 42)mean17.31019.412.280.87median17.08018.842.270.86IQR3.7205.570.130.1Zb-1.690-3.944-3.673-1.506pb0.091 0.000 0.000 0.132IIIb Group(n = 45)mean15.45015.22.220.83median15.13015.882.240.83IQR4.3904.150.1250.095Zb-1.093-0.108-4.283-4.023pb0.2730.914 0.000 0.000 a, Kruskal-Wallis test; b, Mann-Whitney U test, compared to control group; IQR: Interquartile range (IQR) calculated as the upper quartile (XU) – lower quartile (XL) Parameters of descriptive statistics for the content of metals in EPS and serum Healthy control (n = 45) IIIa Group (n = 42) IIIb Group (n = 42) Healthy control (n = 45) IIIa Group (n = 42) IIIb Group (n = 45) a, Kruskal-Wallis test; b, Mann-Whitney U test, compared to control group; IQR: Interquartile range (IQR) calculated as the upper quartile (XU) – lower quartile (XL) Independent correlation of four metals in patients with CP/CPPS and healthy controls As we can see from the Fig. 1, independent correlation of metals in three groups was analyzed. First of all, in the EPS samples, Zn level had a positive correlation with the levels of Ca and Mg in all three groups (all r values > 0.5, and all P < 0.01); the level of Ca was positive correlated with Mg level obviously as well, especially in category IIIa prostatitis group, whose r value = 0.901 (P < 0.01). In addition, EPS Cu level also correlated with EPS Ca level positively (r value = 0.35, P = 0.034) in healthy controls while in category IIIa prostatitis group, EPS Cu level has a negative correlation with EPS Mg (r value = -0.321, P = 0.046). On the other hand, the level of serum Cu had statistically significant positive correlation with serum Ca and Mg in healthy control group, same as the relation between serum Ca and Mg (all P < 0.05). And in the category IIIb prostatitis group, serum Cu correlated significantly with serum Ca (P < 0.01), serum Ca was also positive related with serum Mg (P < 0.01). However, there was no obvious relation among these four trace elements in serum samples of category IIIa prostatitis group. Fig. 1Heatmap analysis of independent correlation of metals in patients with category III prostatitis and healthy controls. a, correlation of EPS metal levels in healthy controls. b, correlation of EPS metal levels in in patients with category IIIa prostatitis. c, correlation of EPS metal levels in patients with category IIIb prostatitis. d, correlation of serum metal levels in healthy controls. e, correlation of serum metal levels in in patients with category IIIa prostatitis. f, correlation of serum metal levels in patients with category IIIb prostatitis. EPS, expressed prostatic secretion. *, P-value < 0.05. **, P-value < 0.01, ***, P-value < 0.001 Heatmap analysis of independent correlation of metals in patients with category III prostatitis and healthy controls. a, correlation of EPS metal levels in healthy controls. b, correlation of EPS metal levels in in patients with category IIIa prostatitis. c, correlation of EPS metal levels in patients with category IIIb prostatitis. d, correlation of serum metal levels in healthy controls. e, correlation of serum metal levels in in patients with category IIIa prostatitis. f, correlation of serum metal levels in patients with category IIIb prostatitis. EPS, expressed prostatic secretion. *, P-value < 0.05. **, P-value < 0.01, ***, P-value < 0.001 Comparison of ratio in related elements between CP/CPPS and healthy controls By comparing the ratio of notably relative trace metals, it was found that in EPS samples, the ratio of Cu/Ca, Zn/Ca, Zn/Mg in both category IIIa and IIIb prostatitis were significantly increased (all P < 0.05). And in serum samples, the ratio of Cu/Ca and Cu/Mg improved prominently in category IIIa prostatitis group (all P < 0.01). The results were listed in the Table 3. Table 3The comparison of elements level between category III prostatitis and healthy controlsElementratioHealthy control(n = 45)Category IIIa prostatitis(n = 42)Category IIIb prostatitis(n = 42) EPS Cu/Cabmean0.0003700.0009250.001405median0.0003210.0005170.001182IQR0.00040.00060.0013P value- 0.038 0.000 Zn/Cabmean0.003710.161520.13724median0.10460.133610.12962IQR0.03900.08960.0890P value- 0.001 0.048 Zn/Mgbmean0.152120.187740.17379median0.136500.160860.14928IQR0.01450.06180.0304P value- 0.000 0.009 Ca/Mgbmean1.38191.25311.3499median1.32721.25661.3597IQR0.26410.32310.5766P value-0.1080.541 Serum Cu/Cabmean0.0069620.0076720.006862median0.0067580.0075230.006716IQR0.00220.00170.0019P value- 0.007 0.842Cu/Mgbmean0.0184560.201140.01863median0.0186970.019940.01863IQR0.00660.00490.0061P value- 0.025 0.733Ca/Mgbmean2.65612.62122.7157median2.64482.61142.6711IQR0.26900.27570.2944P value-0.4020.269b, Mann-Whitney U test, compared to control group; IQR: Interquartile range (IQR) calculated as the upper quartile (XU) – lower quartile (XL) Table 3The comparison of elements level between category III prostatitis and healthy controlsElementratioHealthy control(n = 45)Category IIIa prostatitis(n = 42)Category IIIb prostatitis(n = 42) EPS Cu/Cabmean0.0003700.0009250.001405median0.0003210.0005170.001182IQR0.00040.00060.0013P value- 0.038 0.000 Zn/Cabmean0.003710.161520.13724median0.10460.133610.12962IQR0.03900.08960.0890P value- 0.001 0.048 Zn/Mgbmean0.152120.187740.17379median0.136500.160860.14928IQR0.01450.06180.0304P value- 0.000 0.009 Ca/Mgbmean1.38191.25311.3499median1.32721.25661.3597IQR0.26410.32310.5766P value-0.1080.541 Serum Cu/Cabmean0.0069620.0076720.006862median0.0067580.0075230.006716IQR0.00220.00170.0019P value- 0.007 0.842Cu/Mgbmean0.0184560.201140.01863median0.0186970.019940.01863IQR0.00660.00490.0061P value- 0.025 0.733Ca/Mgbmean2.65612.62122.7157median2.64482.61142.6711IQR0.26900.27570.2944P value-0.4020.269b, Mann-Whitney U test, compared to control group; IQR: Interquartile range (IQR) calculated as the upper quartile (XU) – lower quartile (XL) The comparison of elements level between category III prostatitis and healthy controls b, Mann-Whitney U test, compared to control group; IQR: Interquartile range (IQR) calculated as the upper quartile (XU) – lower quartile (XL) ROC analysis in single element and element ratio with significant changes for the diagnosis in category IIIa and IIIb prostatitis Based on the results obtained above, we constructed a ROC curve by plotting the relationship between sensitivity and specificity to evaluate the diagnostic significance of significantly changed metals (Cu, Zn, Ca, Mg in EPS and Zn, Ca in serum) and element ratios (Cu/Ca, Zn/Ca, Zn/Mg in EPS and Cu/Ca, Cu/Mg in serum) for category IIIa and category IIIb prostatitis. Calculated the Area Under the ROC Curve (AUC), which is a commonly used indicator for evaluating the diagnostic efficacy of potential biomarkers. To begin with, for the diagnosis of category IIIa prostatitis, the AUC of Zn, Ca, Mg, Cu/Ca, Zn/Ca, Zn/Mg in EPS were 0.764, 0.759, 0.796, 0.638, 0.700, 0.791, respectively, which predicts the sensitivity and specificity of category IIIa prostatitis were 76.19% and 73.33%, 76.19% and 68.89%, 85.71% and 71.11%, 78.72% and 81.08%, 88.10% and 42.22%, 90.48% and 62.22%, respectively (all P < 0.05); and serum Zn and Ca also had a high AUC of 0.740 and 0.723 (P < 0.01), followed by serum Cu/Ca and Cu/Mg, whose AUC were 0.663 and 0.636 (P < 0.05). Afterwards, for the diagnostic efficacy of category IIIb prostatitis, EPS Cu and Cu/Ca appeared to have higher AUC of 0.880, 0.901 (P < 0.01) respectively, which predicts the sensitivity and specificity of category IIIb prostatitis were 70.27% and 100.00%, 75.00% and 97.06%; and the AUC of EPS Zn, Ca, Mg, Zn/Ca, Zn/Mg, serum Ca and Mg all were greater than 0.6 (all P < 0.05). Table 4; Figs. 2 and 3 displayed detailed information about the diagnostic threshold of category III prostatitis. Table 4The results of ROC analysis in elements with significant changesAUC95%CIZ P Cut offSensitivitySpecificity Category IIIa prostatitis EPS Zn0.7640.661 to 0.8485.179 < 0.0001 908.335 (µmol/l)76.19073.330Ca0.7590.655 to 0.8445.061 < 0.0001 7.835 (mmol/l)76.19068.890Mg0.7960.696 to 0.8745.991 < 0.0001 6.42 (mmol/l)85.71071.110Cu/Ca0.6380.556 to 0.7862.743 0.006 0.000554.29079.410Zn/Ca0.7000.592 to 0.7943.583 0.000 0.095888.10042.220Zn/Mg0.7910.691 to 0.8715.795 < 0.0001 0.138390.48062.220 Serum Zn0.7400.638 to 0.8254.551 < 0.0001 15.880 (µmol/l)85.71060.000Ca0.7230.620 to 0.8114.199 < 0.0001 2.350 (mmol/l)88.10052.000Cu/Ca0.6630.557 to 0.7592.841 0.0045 0.006885.71052.000Cu/Mg0.6360.529 to 0.7342.334 0.0196 0.016890.48040.000 Category IIIb prostatitis EPS Cu0.8800.784 to 0.9448.496 < 0.0001 7.32 (µmol/l)70.270100.000Zn0.6280.518 to 0.7292.119 0.034 866.85 (µmol/l)42.86082.220Ca0.6520.543 to 0.7512.472 0.013 7.595 (mmol/l)64.29071.110Mg0.6810.572 to 0.7773.072 0.002 6.35 (mmol/l)69.05071.110Cu/Ca0.9010.806 to 0.96010.258 < 0.0001 0.000975.00097.060Zn/Ca0.6230.513 to 0.7251.977 0.048 0.122359.52073.330Zn/Mg0.6620.553 to 0.7602.679 0.007 0.137773.81060.000 Serum Ca0.7550.656 to 0.8385.063 < 0.0001 2.27 (mmol/l)71.11074.000Mg0.7400.640 to 0.8244.611 < 0.0001 0.855 (mmol/l)71.11076.000 Table 4The results of ROC analysis in elements with significant changesAUC95%CIZ P Cut offSensitivitySpecificity Category IIIa prostatitis EPS Zn0.7640.661 to 0.8485.179 < 0.0001 908.335 (µmol/l)76.19073.330Ca0.7590.655 to 0.8445.061 < 0.0001 7.835 (mmol/l)76.19068.890Mg0.7960.696 to 0.8745.991 < 0.0001 6.42 (mmol/l)85.71071.110Cu/Ca0.6380.556 to 0.7862.743 0.006 0.000554.29079.410Zn/Ca0.7000.592 to 0.7943.583 0.000 0.095888.10042.220Zn/Mg0.7910.691 to 0.8715.795 < 0.0001 0.138390.48062.220 Serum Zn0.7400.638 to 0.8254.551 < 0.0001 15.880 (µmol/l)85.71060.000Ca0.7230.620 to 0.8114.199 < 0.0001 2.350 (mmol/l)88.10052.000Cu/Ca0.6630.557 to 0.7592.841 0.0045 0.006885.71052.000Cu/Mg0.6360.529 to 0.7342.334 0.0196 0.016890.48040.000 Category IIIb prostatitis EPS Cu0.8800.784 to 0.9448.496 < 0.0001 7.32 (µmol/l)70.270100.000Zn0.6280.518 to 0.7292.119 0.034 866.85 (µmol/l)42.86082.220Ca0.6520.543 to 0.7512.472 0.013 7.595 (mmol/l)64.29071.110Mg0.6810.572 to 0.7773.072 0.002 6.35 (mmol/l)69.05071.110Cu/Ca0.9010.806 to 0.96010.258 < 0.0001 0.000975.00097.060Zn/Ca0.6230.513 to 0.7251.977 0.048 0.122359.52073.330Zn/Mg0.6620.553 to 0.7602.679 0.007 0.137773.81060.000 Serum Ca0.7550.656 to 0.8385.063 < 0.0001 2.27 (mmol/l)71.11074.000Mg0.7400.640 to 0.8244.611 < 0.0001 0.855 (mmol/l)71.11076.000 The results of ROC analysis in elements with significant changes Fig. 2ROC analysis of trace element for the diagnosis in category IIIa prostatitis. ROC analysis of Zn, Ca, Mg in EPS; Zn, Ca in serum and Cu/Ca, Zn/Ca, Zn/Mg ratio in EPS; Cu/Ca, Cu/Mg ratio in serum for the diagnosis in category IIIa prostatitis ROC analysis of trace element for the diagnosis in category IIIa prostatitis. ROC analysis of Zn, Ca, Mg in EPS; Zn, Ca in serum and Cu/Ca, Zn/Ca, Zn/Mg ratio in EPS; Cu/Ca, Cu/Mg ratio in serum for the diagnosis in category IIIa prostatitis Fig. 3ROC analysis of trace element for the diagnosis in category IIIb prostatitis. ROC analysis of Cu, Zn, Ca, Mg in EPS; Ca, Mg in serum and Cu/Ca, Zn/Ca, Zn/Mg ratio in EPS ROC analysis of trace element for the diagnosis in category IIIb prostatitis. ROC analysis of Cu, Zn, Ca, Mg in EPS; Ca, Mg in serum and Cu/Ca, Zn/Ca, Zn/Mg ratio in EPS Discussion Category III prostatitis is the most common type of chronic prostatitis. Patients with Category III prostatitis always have chronic pelvic pain symptoms and possibly voiding symptoms in the absence of urogenital infections [23], which has a significant negative impact on the quality of life. The etiology of most CP/CPPS cases is unclear, and a debated cause is that CP/CPPS may be due to infections such as bacteria or viruses [23, 24]. K Wenninger et al., reported that the sickness of chronic prostatitis patients is similar to the patients suffering myocardial infarction, angina or Crohn’s disease, according to their sickness impact profile mean total score, which is within the range of scores of those diseases reported in the literature [25]. And it was reported that the prevalence of sexual dysfunction in Chinese males with chronic prostatitis has a negative correlation with age, and the duration of chronic prostatitis (all P < 0.01) [26], several studies also suggested that CP/CPPS might be related to the development of prostate cancer [27, 28]. Because of the accompanied calcification, the effective treatment of category III prostatitis is difficult. CP/CPPS has seriously affected the quality of males’ life. Previous studies suggested that trace metals, such as Zn, play an important role in the development of prostatitis [29, 30]. Therefore, we studied the difference between the concentrations of Cu, Zn, Ca, Mg in healthy controls compared to the patients with CP/CPPS to provide insights of clinical diagnosis with trace metals in CP/CPPS. In our study, Zn was significantly changed. It is an essential trace element, required for maintenance of structural integrity and DNA binding activity in over 2,000 transcription factors [31]. It has been reported that human seminal plasma contains high concentrations of Zn, primarily secreted by the prostate gland [32]. It plays a crucial physiological and pathological role in male health, as it is necessary for preserving the lining of the reproductive organs and may regulate the processes of capacitation and the acrosome reaction, the lack of Zn may weaken the immune and reproductive system [33]. In addition, Paola Bonaventura indicated that acute Zn deficiency could cause a decrease in innate and adaptive immunity, and chronic deficiency might increase inflammation [34]. In our previous study and present study, we found that the level of Zn in EPS was higher in the healthy controls than it in CP/CPPS [35], suggesting that the deficiency of Zn in EPS is closely related to the chronic prostatitis, but the specific mechanism still needs to be explored in depth. Nowadays, biologic Zn therapy is positively effective on sperm motility and the use of biologic Zn supplementation is an efficient way for the treatment of infertile males with chronic prostatitis [36]. In addition, we also found serum Zn level appears to be higher in category IIIa prostatitis, although no direct evidence showed that chronic prostatitis is related to prostate cancer, the level of serum Zn had been reported to be positively associated with prostate cancer risk [37]. Also, many researchers have confirmed that Zn2+ is significantly positively correlated with the risk of prostate cancer [37], when the concentration of Zn2+ and zinc transporter ZIP1 in the body is down-regulated, it is often accompanied by the oncogenic genetic transformation of prostate cells from a normal state to a tumor state with malignant potential [38]. Therefore, we think it is still valuable to further study the role of Zn level between chronic prostatitis and prostate cancer. The next interesting metal is Cu. Cu is an essential cofactor or a structural component in a number of meaningful enzymes, such as Cu/Zn superoxide dismutase (SOD1), which has functions in superoxide detoxification and signaling [39]. However, the over-loaded copper in a free state can trigger the production of a large number of free radicals, leading to the destruction of protein and DNA, and causing the inflammatory changes or even cancer in cells [40, 41]. Our previous study suggested that superoxide dismutase 3 (SOD3) containing catalytic copper and structural inc ions in their active sites is significantly higher in all types of prostatitis than in the control, and is a potential diagnostic marker of nonbacterial prostatitis [35, 39]. O A Adaramoye et al. also reported that the levels of whole blood superoxide dismutase (SOD) were significantly lower (P < 0.05) in the PCa patients [42]. So we speculated that the increase of Cu may be one of the pathogenesis of category III prostatitis, and the prostatitis even cancer may be developed by effecting the expression of these Cu related proteins. In this data, the concentration of EPS Cu had a marked increase only in category IIIb prostatitis and the AUC of EPS Cu, Cu/Ca for predicting category IIIb prostatitis were greater than 0.88 (P < 0.0001), indicating that Cu could be a useful factor in category IIIb prostatitis. Ca and Mg were analyzed in this study as well. Their EPS concentrations were reduced sharply and positively correlated with EPS Zn level in both category IIIa and IIIb prostatitis. Chang-Sheng Zhan et al. found that calcium/calmodulin-dependent kinase III (CaMK4) was increased in the Th17 cells of experimental autoimmune prostatitis, which was activated by intracellular cytosolic Ca2+, Ca2+ -CaMK4-Akt/mTOR-IL-17 A axis inhibition may serve as a promising therapeutic strategy for CP/CPPS [10]. Few studies explore the relationship between Ca, Mg level and CP/CPPS directly. C Y Yang etc. investigated the possible association between the increased risk of prostate cancer and the concentrations of Ca and Mg in drinking water from municipal supplies, and they found that the relationship between Ca levels in drinking water and prostate cancer was not statistically clear while Mg intake from drinking water and other dietary sources may has a significant protective effect against the risk of prostate cancer development [43]. Besides, both EPS and serum Ca, Mg had a higher AUC for predicting category IIIa and IIIb prostatitis. Although we have obtained some great discoveries through this study, some limitations are still obvious. The type of design of clinical trial was non-randomized, non-blinded. The total samples are small, and all samples were collected from patients who attended the healthy physical examination in the Guilin area in Guangxi, China, and the results could not be extrapolated to the whole population reliably, and in the future, it is necessary to use multicenter, randomized, double-blind clinical randomized controlled trials in further research to confirm our findings. And the trace metal elements may be also related to the patient’s condition and psychological factors, which is also the direction of our future research. In future studies, we will further explore the relationship between trace metal elements and prostatitis by combining the relevant standards of UPOINT classification. Based on results above, further learning the function of these metals in category III prostatitis is important, and the specific role of these metals related proteins may also have potential research value. Conclusion Our study demonstrates that the concentration of Cu, Mg, Ca, Zn in EPS and serum samples with category III prostatitis have notable changes compared with those in healthy controls, the level of Mg, Zn/Mg in EPS might be promising to diagnose category IIIa prostatitis, and level of Cu and Cu/Ca in EPS could diagnose category IIIb prostatitis. It is recommended that these four elements may play important roles in the process of category III prostatitis, which provides a new strategy and further support for the diagnosis and treatment of this disease. And the specific functions of trace metals in category III prostatitis might need further investigation.